Evidence map›Paper›PMID 34117055›Full record

ArticleScience advances2021

Hyaluronic acid conjugates for topical treatment of skin cancer lesions.

Vinu Krishnan, Kevin Peng, Apoorva Sarode, Supriya Prakash, Zongmin Zhao, Sergey K Filippov, Kristina Todorova, Brittney R Sell, Omar Lujano, Shirin Bakre and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Materials today. Bio · 2024
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Vinu KrishnanSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0003-0098-7864
Kevin PengSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0002-0926-0592
Apoorva SarodeSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0003-4096-7534
Supriya PrakashSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0003-0772-8822
Zongmin ZhaoSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0001-8979-844X
Sergey K FilippovSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0002-4253-5076
Kristina TodorovaCutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Building 149 13th Street, Charlestown, MA 02129, USA.
Brittney R SellDepartments of Anatomic Pathology and Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.ORCID 0000-0002-9341-2009
Omar LujanoDepartment of Molecular, Cellular, and Developmental Biology (MCDB), University of California, Santa Barbara, Santa Barbara, CA 93117, USA.ORCID 0000-0002-5478-4571
Shirin BakreSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Anusha PusuluriSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.
Douglas VogusSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA.ORCID 0000-0003-1879-047X
Kenneth Y TsaiDepartments of Anatomic Pathology and Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.ORCID 0000-0001-5325-212X
Anna MandinovaCutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Building 149 13th Street, Charlestown, MA 02129, USA.
Samir MitragotriSchool of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138, USA. mitragotri@seas.harvard.edu.ORCID 0000-0002-2459-8305
Harvard University · USMoffitt Cancer Center · USBroad Institute · USMassachusetts General Hospital · USUniversity of California, Santa Barbara · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin cancer is one of the most common types of cancer in the United States and worldwide. Topical products are effective for treating cancerous skin lesions when surgery is not feasible. However, current topical products induce severe irritation, light-sensitivity, burning, scaling, and inflammation. Using hyaluronic acid (HA), we engineered clinically translatable polymer-drug conjugates of doxorubicin and camptothecin termed, DOxorubicin and Camptothecin Tailored at Optimal Ratios (DOCTOR) for topical treatment of skin cancers. When compared to the clinical standard, Efudex, DOCTOR exhibited high cancer-cell killing specificity with superior safety to healthy skin cells. In vivo studies confirmed its efficacy in treating cancerous lesions without irritation or systemic absorption. When tested on patient-derived primary cells and live-skin explants, DOCTOR killed the cancer with a selectivity as high as 21-fold over healthy skin tissue from the same donor. Collectively, DOCTOR provides a safe and potent option for treating skin cancer in the clinic.

Indexed as

Skin DiseasesSkin NeoplasmsAdministration, TopicalCamptothecinDoxorubicinHumansHyaluronic AcidCamptothecinDoxorubicinHyaluronic Acid

Identifiers

PMID34117055
PMCPMC8195472
OpenAlexW3169477387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.